Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Reiberger
Jonel Trebicka

Showing results (171-180 of 971) with videos related to

Pageof 98
Sort By:
Journal of Hepatology|April 14, 2021
Reply to: "Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease"Benedikt Simbrunner, Dalila Costa, Thomas Reiberger
Liver International : Official Journal of the International Association for the Study of the Liver|July 7, 2020
Combination of phosphodiesterase-5-inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunctionFrank E Uschner, Kathleen Glückert, Rafael Paternostro, et al.
Plos One|April 5, 2017
High risk of misinterpreting liver and spleen stiffness using 2D shear-wave and transient elastography after a moderate or high calorie mealMaria Kjærgaard, Maja Thiele, Christian Jansen, et al.
Scientific Reports|March 30, 2021
Impact of transjugular intrahepatic portosystemic shunt creation on the central lymphatic system in liver cirrhosisClaus Christian Pieper, Andreas Feißt, Carsten Meyer, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 6, 2021
ReplyMattias Mandorfer, Thomas Reiberger, Mathias Jachs
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 11, 2025
ReplyThomas Reiberger, Nina Dominik, Michael Trauner
Alimentary Pharmacology & Therapeutics|December 21, 2024
Letter: Insulin-Like Growth Factor-1 in Cirrhosis Is Linked to Hepatic Dysfunction and Fibrogenesis and Predicts Liver-Related MortAlity-Authors' ReplyLukas Hartl, Michael Schwarz, Thomas Reiberger
Alimentary Pharmacology & Therapeutics|January 15, 2023
Letter: chronic HDV infection-is ignorance bliss? Authors' replyMathias Jachs, Thomas Reiberger, Peter Ferenci
Alimentary Pharmacology & Therapeutics|May 26, 2026
Editorial: Bile Acids Under Bulevirtide-A Pharmacodynamic Signature, Not a Prognostic Biomarker. Authors' ReplyMarlene Hintersteininger, Thomas Reiberger, Mathias Jachs
Gut|October 22, 2020
Hepatic inflammasome activation as origin of Interleukin-1α and Interleukin-1β in liver cirrhosisMichael Praktiknjo, Robert Schierwagen, Sofia Monteiro, et al.
Pageof 98

Showing results (171-180 of 971) with videos related to

Sort By:
Pageof 98
Journal of Hepatology|April 14, 2021
Reply to: "Presepsin as a biomarker of inflammation and prognosis in decompensated liver disease"Benedikt Simbrunner, Dalila Costa, Thomas Reiberger
Liver International : Official Journal of the International Association for the Study of the Liver|July 7, 2020
Combination of phosphodiesterase-5-inhibitors and beta blockers improves experimental portal hypertension and erectile dysfunctionFrank E Uschner, Kathleen Glückert, Rafael Paternostro, et al.
Plos One|April 5, 2017
High risk of misinterpreting liver and spleen stiffness using 2D shear-wave and transient elastography after a moderate or high calorie mealMaria Kjærgaard, Maja Thiele, Christian Jansen, et al.
Scientific Reports|March 30, 2021
Impact of transjugular intrahepatic portosystemic shunt creation on the central lymphatic system in liver cirrhosisClaus Christian Pieper, Andreas Feißt, Carsten Meyer, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 6, 2021
ReplyMattias Mandorfer, Thomas Reiberger, Mathias Jachs
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 11, 2025
ReplyThomas Reiberger, Nina Dominik, Michael Trauner
Alimentary Pharmacology & Therapeutics|December 21, 2024
Letter: Insulin-Like Growth Factor-1 in Cirrhosis Is Linked to Hepatic Dysfunction and Fibrogenesis and Predicts Liver-Related MortAlity-Authors' ReplyLukas Hartl, Michael Schwarz, Thomas Reiberger
Alimentary Pharmacology & Therapeutics|January 15, 2023
Letter: chronic HDV infection-is ignorance bliss? Authors' replyMathias Jachs, Thomas Reiberger, Peter Ferenci
Alimentary Pharmacology & Therapeutics|May 26, 2026
Editorial: Bile Acids Under Bulevirtide-A Pharmacodynamic Signature, Not a Prognostic Biomarker. Authors' ReplyMarlene Hintersteininger, Thomas Reiberger, Mathias Jachs
Gut|October 22, 2020
Hepatic inflammasome activation as origin of Interleukin-1α and Interleukin-1β in liver cirrhosisMichael Praktiknjo, Robert Schierwagen, Sofia Monteiro, et al.
Pageof 98